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Background: Acquired Immune Deficiency Syndrome (AIDS) is the advanced stage of infection caused by Human
Immunodeficiency Virus (HIV). HIV/AIDS had a great impact on society, both as an illness and as a source of discrimination.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) are structurally diverse group of compounds which binds to
Reverse Transcriptase (RT) enzyme of HIV. Like other anti-HIV drugs, long-term clinical effectiveness of approved NNRTIs
has been hampered due to the rapid development of drug resistance. So, there is an urgent need to discover the NNRTIs,
which can be effective against the drug sensitive as well as drug resistant strains of HIV-1 RT.
Results: Two series of novel thirty, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogues (5a-o) and (8a-o) were
designed and synthesized as inhibitor of HIV-1 reverse transcriptase. All the synthesized compounds were characterized
by infrared spectroscopy, proton nuclear magnetic resonance spectroscopy, mass spectroscopy and evaluated for
in-vitro RT inhibitory activity. Among the tested compounds, eighteen compounds exhibited more than 50 % inhibition
at tested 100 μM concentration, in which two compounds 8h and 8l showed promising inhibition (74.82 and 72.58 %)
respectively. The preliminary structure–activity relationship (SAR) of the test compounds and docking studies of the
two significantly active compounds 8h and 8l were performed to examine their putative binding with HIV-RT. Predicted
physiochemical parameters of the synthesized compounds were within the acceptable range of drugable properties.
Conclusion: The results obtained from this investigation revealed that, the synthesized compounds (5a-o) and (8a-o)
showed moderate to promising HIV-1 RT inhibition activity. The overall SAR studies can help in identification of further
lead as well as in designing of newer potential inhibitor of HIV-1 RT.
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Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
are important components of the preferred combin-
ation of antiretroviral therapy for the treatment of HIV
infection [1, 2]. Tetrahydroisoquinoline (THIQ) scaf-
fold containing natural products as well as synthetic de-
rivatives have privileged position in the medicinal
chemistry and reported for different biological activities
like anti-microbial [3], anti-cancer [4], anti-viral [5],
anti-HIV [6] and others [7, 8]. Natural THIQs as* Correspondence: murugesan@pilani.bits-pilani.ac.in
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creativecommons.org/publicdomain/zero/1.0inhibitors of HIV-1 and its enzyme reverse transcript-
ase were continuously reported in the literature. For ex-
ample, michellamine-B (Fig. 1) an alkaloid from
Ancistrocladus korupenis was reported for anti-HIV activ-
ity [9]. Other THIQ derivatives (Fig. 1) reported in the lit-
erature against reverse transcriptase of HIV-1 were
chelidoneme, magnoflorine [10], O-methyl psychotrine
sulphate [11]. Another series of benzyl THIQ derivatives,
isolated from the leaves of Nelumbo nucifera contains R-
coclaurine (Fig. 1) as active constituent also showed po-
tent anti-HIV activity [12].
Literature study revealed that, apart from the THIQs
obtained from the natural resources, their syntheticarticle distributed under the terms of the Creative Commons Attribution
/by/4.0), which permits unrestricted use, distribution, and reproduction in any
rly credited. The Creative Commons Public Domain Dedication waiver (http://
/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Natural THIQ derivatives reported as inhibitors of HIV-1 and target Reverse Transcriptase
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RT. In a similar study, two novel derivatives of THIQ
(Fig. 2a and b) showed excellent potency against wild
strains of HIV-1 by inhibiting RT enzyme [13]. Another
study [14] revealed that, compounds having pyrazine ring
connected to the tetrahydroisoquinoline via thiaglycina-
mide linker (Fig. 2c) and its bioisosters (Fig. 2d), exhib-
ited good potency against HIV-1 RT with IC50 4.10
and 1.7 μM respectively. In another study, a series of
1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolines were
synthesized and assayed for anti HIV-1 activity, most active
compound of the series (Fig. 2e) showed good potency with
EC50 16.9 μM [6].
Even though, NNRTIs are structurally diverse com-
pounds, still they contain numerous ubiquitous fragments
in their structures and possess a common pharmacopho-
ric model. This model includes an aromatic ring able to
participate in pi-pi stacking interactions, amide or thio-
amide moieties capable of hydrogen bonding and one or
more hydrocarbon-rich domain that participate in hydro-
phobic interactions [15]. So considering these crucial
pharmacophoric features of HIV-1 RT inhibitor, we gener-
ated a common pharmacophoric model (Fig. 2f). Based
upon this model, new tetrahydroisoquinoline prototypes 5
and 8 were designed (Fig. 2). Further using these proto-
types, two series of novel thirty compounds 5a-o and 8a-owere synthesized and evaluated for in-vitro RT inhibitory
activity. Structure activity relationship (SAR) studies of the
test compounds were investigated based upon the in-vitro
RT inhibitory potency. Molecular docking studies of most
active compound were also carried out in order to know
exact binding pattern at the active site of the receptor.
These studies may help in further lead identification and
designing of more potent molecules against HIV-1 RT.
Methods
Chemistry
All solvents and reagents purchased from Sigma or Merck
companies were used as received without further purifica-
tion. Solvent system used throughout experimental work for
running TLC was ethyl acetate and hexane mixture (in suit-
able proportion) in order to monitor the progress of reac-
tions. Melting points were uncorrected and determined in
open capillary tubes on a Precision Buchi B530 (Flawil,
Switzerland) melting point apparatus containing silicon oil.
IR spectra of the synthesized compounds were recorded
using FTIR spectrophotometer (Shimadzu IR Prestige 21,
India). 1H NMR spectra were recorded on a Bruker DPX-
400 spectrometer (Bruker India Scientific Pvt. Ltd., Mumbai)
using TMS as an internal standard (chemical shifts in δ).
ESMS were recorded on MICROMASS Quattro-II LCMS
system (Waters Corporation, Milford, USA).
Fig. 2 Structure of tetrahydroisoquinolines (2a, 2b, 2c and 2e) and related analogue (2d) as potent inhibitor of HIV-1 and HIV-1 RT along with
proposed pharmacophoric model (2f) and designed prototypes (5 and 8)
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Current study involved the use of enzymatic assay for
in-vitro screening of compounds against HIV-1 RT, apart
from this human being or other animals were not used
in the study. Synthesised compounds were evaluated for
in-vitro HIV-1 RT inhibitory potency using colorimetric
assay method (Roche diagnostics) and carried out as de-
scribed in the kit protocol. Marketed drug efavirenz was
used as reference during the study. Test is based uponthe colorimetric enzyme immunoassay, which quantita-
tively determines the retroviral reverse transcriptase ac-
tivity. 100 μM concentrations of the test compounds
were used for in-vitro assay. Briefly, the reaction mixture
was set with template primer complex, RT enzyme and
dNTPs in the lysis buffer with or without inhibitors. Re-
action mixture was incubated at 37 °C for 1 h and then
transferred to streptavidine-coated microtitre plate
(MTP). The biotin-labeled dNTPs that are incorporated
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streptavidine. The unbound dNTPs were washed using
wash buffer and anti-DIG-POD was added to the MTP.
The DIG-labeled dNTPs incorporated in the template
were bound to anti-DIG-POD antibody. The unbound
anti-DIG-POD was washed and the peroxide substrate
(ABST) was added to the MTP. A colored reaction prod-
uct was produced during the cleavage of the substrate
catalyzed by a peroxide enzyme. The absorbance of the
sample was determined at optical density (OD) of
405 nm using micro titer plate ELISA reader.
The % inhibition of HIV-1 RT was calculated using
the following formula:
% inhibition ¼ 100− OD at 405 nm with inhibitor




In-silico docking studies were performed using Glide 5.9
[16] running on maestro version 9.4, to investigate the
exact binding mode of most active compound in NNIBP
(Non-Nucleoside Inhibitory Binding Pocket) of HIV-1
RT [17]. Enzyme used for the docking study was wild
RT, retrieved from RCSB Protein Data Bank (PDB id:
3MEE) in complex with rilpivirine. Protein preparation
wizard of Schrödinger suite was used for preparation of
retrieved 3MEE protein. Protein was pre-processed sep-
arately by deleting the substrate co-factor as well as the
crystallographically observed water molecules (water
without H bonds), followed by optimization of hydrogen
bonds. After assigning charge and protonation state,
finally energy was minimized with Root Mean Square
Deviation (RMSD) value of 0.30 Å using Optimized Po-
tentials for Liquid Simulations-2005 (OPLS-2005) force
field [18]. Prepared protein and co-crystallized ligand
was employed to build energy grids using the default
value of protein atom scaling (1.0 Å) within a cubic box
of dimensions, centered on the centroid of the X-ray lig-
and pose. The structures of the designed analogues were
drawn using ChemSketch and converted to 3D structure
with the help of 3D optimization tool. By using the Lig-
Prep 2.6 [19] module, the drawn ligands were geometry
optimized. Partial atomic charges were computed using
OPLS-2005 force field. Finally, 32 poses were includedScheme 1 Synthesis of final compounds (5a-o), reagents and conditions: (with different tautomeric and steric features for docking
studies. Finally, prepared ligands were docked with pre-
pared protein using Glide 5.9 module, in extra precision
mode (XP). The best docked pose (with lowest Glide
score value) obtained from Glide was analyzed. RMSD
value was calculated between the experimental binding
mode of ligand rilpivirine as in X-ray co-crystallized
pose in 3MEE and Glide re-docked pose to ensure ac-
curacy and reliability of the docking procedure. Physico-
chemical parameters of the synthesized compounds were
in-silico predicted in order to evaluate their drug like-
ness properties using Qik-prop 3.7 [20] module of
Schrödinger and online tool AdmetSAR [21].Results and discussion
Chemistry
The synthesis of target compounds 5a-o and 8a-o is
outlined in Schemes 1 and 2 respectively. In Scheme 1,
reaction of substituted anilines 1a-o and chloroacetyl
chloride 2 in DCM, in the presence of triethylamine as a
base afforded substituted 2-chloro-N-phenylacetamide
(3a-o), which on subsequent treatment with hydrochlor-
ide salt of 6,7-dimethoxy tetrahydroisoquinoline (4), in
acetonitrile in the presence of potassium carbonate as
base afforded the title compounds (5a-o). In Scheme 2,
reaction of chloroacetyl chloride (2) and 6,7-dimethoxy
tetrahydroisoquinoline (4) in DCM as solvent and
triethylamine as base gave intermediate 6. Further, for
the synthesis of final compounds of series 8, reaction
conditions were standardized using the conventional as
well as microwave assisted synthetic approaches. Finally
reaction of intermediate 6 with substituted anilines (7a-o)
under solvent free, microwave condition in the presence
of potassium carbonate as base afforded the final com-
pounds in comparatively better yield than the conven-
tional synthetic approach (8a-o).
All the synthesized compounds were characterized by
spectral analysis. The IR spectra of 5a-o showed the ex-
pected absorption bands of amide hydrogen (−CONH-)
at the region 3200–3500 cm−1 (strong, broad). Likewise
compounds 8a-o contained secondary nitrogen (−NH-)
which showed absorption peak in the region 3250–
3400 cm−1 (strong, sharp). All the synthesized com-
pounds possessed characteristic amide carbonyl (C =O)a) DCM, Et3N, 0 °C-rt, 2 h; (b) ACN, K2CO3, Reflux 3–5 h
Scheme 2 Synthesis of final compounds (8a-o), reagents and conditions: (a) DCM, Et3N, 0 °C-rt, 2.5 h; (b) neat, K2CO3, microwave irradiation at
300 W for 2 to 4.5 min
Chander et al. Chemistry Central Journal  (2015) 9:33 Page 5 of 13peak at 1630–1690 cm−1 in its expected region. 1H
NMR signals and proton counting of the title com-
pounds were also observed in their expected region.
ESI-MS of the synthesized compounds showed the cor-
responding M + 1 peak.
In-vitro HIV-1 RT screening
In-vitro studies of the test compounds (5a-o), showed
weak to moderate activity against HIV-1 RT (Table 1).
Among the tested compounds, five compounds (5d, 5f,
5h, 5n and 5o) showed more than 50 % enzyme inhib-
ition at tested 100 μM concentration. Substitutions with
electron donating groups especially at the para position
of the phenyl ring enhanced the potency against HIV-1
RT, for example p-methyl substituted compound 5d
(52.46 % inhibition) exhibited 1.5 times more potent as
compared to un-substituted one (5a) (34.32 % inhib-
ition). Similarly, p-methoxy substituted compound 5f is
more potent (56.23 % inhibition) as compared to the
m-substituted compound 5e (44.21 % inhibition). Sub-









5a H 34.32 8a 2-OCH3 45.31
5b 2-CH3 36.23 8b 3-OCH3 51.32
5c 3-CH3 39.51 8c 4-OCH3 57.45
5d 4-CH3 52.46 8d 3-F 48.37
5e 3-OCH3 44.21 8e 4-F 53.93
5f 4-OCH3 56.23 8f 2-Cl 61.38
5g 4-F 28.45 8g 3-Cl 63.74
5h 2-Cl 52.34 8h 4-Cl 74.82
5i 3-Cl 37.26 8i 2-Br 63.38
5j 4-Cl 33.65 8j 3-Br 60.46
5k 4-NO2 42.78 8k 4-Br 68.63
5l 3-CF3 30.64 8l 4-CN 72.58
5m 2,6-dimethyl 48.36 8m 3-Aceto 54.75
5n 3,4-dimethyl 58.12 8n 3-CF3 66.74
5o 2-CH3-5-Cl 53.76 8o 2,5 dimethyl 63.64
Efavirenz 98.12
aData are indicated as percentage of inhibition of HIV-1 RT at 100 μM concentrationpotency against HIV-1 RT, halogen groups like chloro
substituted compounds (5h, 5i and 5j) followed the
pattern in decreasing order of potency ortho >meta >
para. Similarly compound 5g having p-fluoro substitu-
tion decreased the potency, while substitution of
phenyl ring with p-nitro group (5k) slightly enhanced
the potency. Compound 5l with strong electron with-
drawing group (m-trifluoromethyl) also showed less
potency against HIV-1 RT. Upon di-substitution at
phenyl ring, good enhancement in the potency was
observed (compounds 5m, 5n and 5o). Compound 5n
(3,4-dimethyl substitution) showed highest potency
(58.12 % inhibition) among the tested 5a-o series of
compounds.
Majority of compounds in 8a-o series showed more
than 50 % inhibition of HIV-1 RT at 100 μM tested con-
centration except compounds 8a and 8d (Table 1). Sub-
stitutions with electron-donating groups at phenyl ring
like methoxy (compounds 8a, 8b and 8c) showed mod-
erate potency against RT. Compounds substituted with
electron withdrawing groups like fluoro (8d and 8e), po-
tency was not changed much may be due to its very
small size and very strong electron withdrawing nature.
However substitution with other electron withdrawing
groups like chloro, bromo, nitro and aceto (8f, 8g, 8h,
8i, 8j, 8k, 8l, 8m and 8n) on the phenyl ring increased
the potency. Compounds having chloro substitution at
the ortho and meta position (8f and 8g) did not showed
any significant difference in potency, but substitution at
para position (8h) significantly enhanced the potency
(74.82 % inhibition of HIV-RT). Like chloro substituted
compounds almost similar pattern of potency was exhib-
ited by the bromo substituted compounds (8i, 8j and 8k).
Substitution with cyano, an electron withdrawing group at
the para position (8l) also significantly increased the po-
tency. Apart from this, compound 8m and 8n having
aceto and trifluoromethyl group at the meta position
showed moderate to good potency (54.75 and 66.74 %
inhibition) respectively against RT. Further, dimethyl
substituted compound (8o) found to be more potent as
compared to the single methoxy substituted compounds
(8a, 8b and 8c). Among all the tested compounds,
analogue (8h) exhibited highest potency (74.82 % inhib-
ition of HIV-1 RT).
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In order to predict the exact binding mode and to
know the interactions of most active compounds (8h
and 8l) within NNIBP of HIV-1 RT, docking studies
were carried out on X-ray coordinates of HIV-1 RT
enzyme (PDB ID: 3MEE). To evaluate the accuracy
and reliability of the docking procedure, co-
crystallized native ligand rilpivirine was removed from
its binding site of 3MEE and again subjected to dock
into the same binding pocket (Fig. 3). As a result, the
value of RMSD obtained between experimental bind-
ing mode as in X-ray and re-docked pose for rilpivir-
ine was 0.8, which suggested that docking procedure
could be relied onto predict the exact binding mode
of the designed compounds.
Docking studies of the reference drug efavirenz
showed that, its cyclopropyl ring extents towards deep
hydrophobic pocket surrounded by amino acids Tyr-
188, Tyr-181, Leu-100 and Trp-229 and chloro phenyl
ring showed hydrophobic interaction with Tyr-318
and Val-106 residues (Fig. 4). Apart from hydrophobic
interaction, NH of the efavirenz form strong hydrogen
bond interaction with the C = O of the Lys-101. These
strong hydrophobic and hydrophilic interactions of
efavirenz with receptor may accounts for good in-
silico activity.
However, analysis of best docked pose of two most
active compounds 8h and 8l revealed that their 6,7-
dimethoxytetrahydroisoquinoline nucleus form strong
hydrophobic interaction with amino acids like Tyr-
188, Tyr-181 and Trp-229 (Figs. 5 and 6). Other
hydrophobic wing of 8h (p-chloro phenyl) showed
hydrophobic interactions with Val-106 and Tyr-318
(Fig. 5b), while second wing of 8h (p-cyano phenyl)
exhibited hydrophobic interactions predominantly
with Tyr- 318 (Fig. 6b). Moreover NH of both ligands
form hydrogen bond interaction with Lys-101, which
is generally considered crucial for the RT inhibition
activity and additionally enhanced the binding affinity
of ligands 8h and 8l with HIV-1 RT. Substitution atFig. 3 Re-docked pose of rilpivirine (green) with X-ray co-crystallized
(gray) structure in NNIBP of 3MEEthe para position of phenyl especially with electron
withdrawing groups of moderate size like chloro and
cyano in 8h and 8l respectively enhanced the hydro-
phobic area of contact between the ligand-receptor
complex and may be responsible for their significant
in-vitro activity.
Predicted in-silico drug likeness properties
ADMET (Absorption, Distribution, Metabolism, Excre-
tion and Toxicological) parameters play very crucial role
in the discovery and development of novel drugs. Cur-
rently available drugs in the market possess a balance of
desirable ADMET properties and intrinsic potency.
Lipinski's rule of five (RO5) helps to predict the presence
of drug-like physicochemical properties in a given com-
pound, these properties affect as drug’s pharmacokinet-
ics (ADMET) in the human body. Drug candidates that
comply with the Lipinski rule of five have less failure
rate during the clinical trial.
So in our study, physicochemical parameters of the
synthesized compounds were in-silico generated in
order to evaluate their drug likeness properties using
Qik-prop module of Schrödinger and online tool
AdmetSAR (Table 2). Results obtained in this study re-
vealed that, the in-silico generated parameters of all
synthesized derivatives were within the acceptable
range of drug-likeness. General range of physicochemi-
cal parameters for drug likeness varies as: Mol. wt.
(150–650), H bond donor (≤5), H bond acceptor (≤10)
Log Po/w (−0.4 to 5.6), Log S (−6.5 to −0.5), Log BB
(−3.0 to 1.2), % Human oral absorption (≥80 % is high
and ≤25 % is poor).
Experimental
General procedure for the synthesis of substituted
2-chloro-N-phenylacetamide (3a-o)
Chloroacetyl chloride 2 (1.68 g, 1.5 mmol) was added
dropwise to the ice cooled stirring solution of
substituted anilines (1a-o) (1.5 mmol) in DCM, in the
presence of triethyl amine (4.5 mmol, 0.46 g) as base.
Reaction was further stirred at rt for 2 to 3 h, pro-
gress of the reaction was monitored with TLC. After
completion of reaction, DMC layer was washed with
distilled water, dried over sodium sulphate and evapo-
rated on rotary evaporator to yield the intermediates
(3a-o).




ates 3a-o, 1 mmol) was added to the stirring reaction
mass of 4, in acetonitrile in the presence of
Fig. 4 Docking poses of efavirenz at NNIBP of RT enzyme, showing two dimensional interactive diagram (a), hydrophobic and hydrogen bond
interaction (b) represented by green and pink dotted lines respectively
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ther allowed to reflux for 5 to 7 h, progress of the re-
action was monitored by the TLC (Scheme 1). After
completion of reaction, solvent acetonitrile was evap-
orated on rotary evaporator; water was added to the
reaction mixture and extracted twice with equal vol-
ume (25 ml) of ethyl acetate. Combined ethyl acetate
layer was washed with brine water, dried over sodium
sulphate and evaporated on rotary evaporator to af-
ford the final compounds 5a-o.Fig. 5 Docked pose of 8h at NNIBP of RT enzyme, showing two dimensional
(b) represented by green and pink dotted lines respectivelySynthesis of 2-chloro-1-(3,4-dihydro-6,7-dimethoxyisoquinolin-
2(1H)-yl)ethanone (6)
Chloroacetyl chloride 2 (2.24 g, 20 mmol) was added
dropwise to the ice cooled stirring solution of starting
material 4 (4.6 g, 20 mmol) in DCM, in a round-bottom
flask using triethyl amine (7.0 ml, 50 mmol,) as base
(Scheme 2). Reaction mixture was further stirred at rt
for 2.5 h until completion as per TLC. After completion
of reaction, DMC layer was washed with distilled water
once and then with brine water and dried over sodiuminteractive diagram (a), hydrophobic and hydrogen bond interaction
Fig. 6 Docked pose of 8l at NNIBP of RT enzyme, showing two dimensional interactive diagram (a), hydrophobic and hydrogen bond interaction
(b) represented by green and pink dotted lines respectively
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afford the titled compounds.
General procedure for the synthesis of substituted
1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-
(phenylamino) ethanone using Microwave irradiation (8a-o)
2-methoxyaniline (7a) (0.12 g, 1 mmol) and chloro inter-
mediate 6 (0.27 g, 1 mmol) was taken in microwave re-
action vial in presence of potassium carbonate as base
(0.347 g, 2.5 mmol) (Scheme 2). The microwave oven
model Cata RI was programmed to 300 W at 100 °C for
2 to 4.5 min. The reaction was monitored using TLC.
After completion of reaction, ice water was added to the
reaction mixture which resulted the precipitation of the
product. The solid product was filtered off and washed
with excess cold water and dried to afford product 8a.
Similar apporoach was followed for the synthesis of rest
of the compounds (8b-o).
The spectral characterization of the synthesized derivatives
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-
phenylacetamide (5a)
Yield 73 %; white solid, MF: C19H22N2O3; MW: 326.16;
MP: 151–154 °C; IR (KBr, ν, cm−1): 3288, 3001, 2821,
2775, 1693, 1517, 1423, 1228, 1139, 1105; 1H NMR
(400 MHz, CDCl3) δ 9.21 (s, 1H), 7.59 (dd, J = 8.6,
1.1 Hz, 2H), 7.39 – 7.31 (m, 2H), 7.14 (d, J = 7.4 Hz, 1H),
6.67 (s, 1H), 6.55 (s, 1H), 3.88 (d, J = 12.2 Hz, 6H), 3.77
(s, 2H), 3.34 (s, 2H), 2.92 (s, 4H); MS: m/z 327 (M+ 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-o-
tolylacetamide (5b)
Yield 76 %; white solid, MF: C20H24N2O3; MW: 340.18; MP:
137–139 °C; IR (KBr, ν, cm−1): 3294, 2975, 2914, 2829, 1670,
1490, 1251, 1226, 1139, 1013; 1H NMR (400 MHz, CDCl3) δ9.33 (s, 1H), 8.14 (d, J= 8.1 Hz, 1H), 7.25 (s, 1H), 7.17 (d, J=
7.2 Hz, 1H), 7.06 (td, J= 7.5, 1.2 Hz, 1H), 6.66 (s, 1H), 6.54
(s, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.79 (s, 2H), 3.38 (s, 2H),
2.95 (d, J= 3.8 Hz, 4H), 2.20 (s, 3H); MS: m/z 341 (M+ 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-m-
tolylacetamide (5c)
Yield 78 %; white solid, MF: C20H24N2O3; MW: 340.18; MP:
131–133 °C; IR (KBr, ν, cm−1): 3286, 3010, 2949, 2833, 1683,
1519, 1489, 1220, 1143, 1024; 1H NMR (400 MHz, CDCl3)
δ 9.17 (s, 1H), 7.40 (d, J = 11.8 Hz, 2H), 7.23 (t, J = 7.7 Hz,
1H), 6.95 (d, J = 7.6 Hz, 1H), 6.67 (s, 1H), 6.55 (s, 1H), 3.88
(d, J = 12.3 Hz, 6H), 3.74 (d, J = 17.9 Hz, 2H), 3.33 (s, 2H),
2.98 – 2.80 (m, 4H), 2.36 (s, 3H); MS: m/z 341 (M+ 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-p-
tolylacetamide (5d)
Yield 81 %; white solid, MF: C20H24N2O3; MW: 340.18;
MP: 151–153 °C; IR (KBr, ν, cm−1): 3267, 2943, 2827,
2779, 1685, 1517, 1462, 1253, 1196; 1H NMR (400 MHz,
CDCl3) δ 9.14 (s, 1H), 7.51 – 7.42 (m, 2H), 7.15 (d, J =
8.2 Hz, 2H), 6.67 (s, 1H), 6.55 (s, 1H), 3.88 (d, J = 12.1 Hz,
6H), 3.76 (s, 2H), 3.32 (s, 2H), 2.91 (d, J = 3.1 Hz, 3H),
2.33 (s, 3H); MS: m/z 341 (M+ 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-(3-
methoxyphenyl)acetamide (5e)
Yield 76 %; white solid, MF: C20H24N2O4; MW: 356.18; MP:
139–141 °C; IR (KBr, ν, cm−1): 3277, 2922, 2829, 1685, 1597,
1523, 1465, 1255, 1139, 1005; 1H NMR (400 MHz, CDCl3)
δ 9.17 (s, 1H), 7.42 (d, J = 11.7 Hz, 2H), 7.24 (t, J = 7.8 Hz,
1H), 6.93 (d, J = 7.8 Hz, 1H), 6.66 (s, 1H), 6.54 (s, 1H), 3.88
(d, J = 12.3 Hz, 6H), 3.82 (s, 3H), 3.72 (d, J = 17.9 Hz, 2H),
3.32 (s, 2H), 2.96 – 2.78 (m, 4H); MS: m/z 357 (M+ 1).
Table 2 In-silico predicted physiochemical parameters of the test compounds
Compound code Mol. wt. Mol. Vol. H bond donor H bond acceptor Log Po/w Log S Log BB Human oral absorption (%)
5a 326.39 1099.45 1 5 3.12 −3.62 0.19 98.23
5b 340.42 1135.79 1 5 3.3 −3.75 0.23 97.35
5c 340.42 1160.54 1 5 3.4 −4.21 0.17 96.65
5d 340.42 1160.72 1 5 3.43 −4.21 0.17 97.78
5e 356.42 1174.76 1 6 3.21 −3.83 0.11 97.21
5f 356.42 1175.85 1 6 3.21 −3.85 0.11 95.16
5g 344.38 1116.84 1 5 3.36 −4.01 0.30 96.45
5h 360.83 1137.53 1 5 3.59 −4.18 0.40 97.32
5i 360.83 1144.61 1 5 3.62 −4.36 0.37 96.15
5j 360.83 1144.83 1 5 3.62 −4.38 0.35 95.68
5k 371.39 1173.43 2 6 2.40 −3.78 −0.91 78.41
5l 394.39 1199.11 1 5 4.11 −5.08 0.45 94.32
5m 354.44 1187.59 1 5 3.66 −4.14 0.30 95.41
5n 354.44 1211.12 1 5 3.70 −4.62 0.17 97.16
5o 374.86 1194.24 1 5 3.92 −4.63 0.44 98.24
8a 356.42 1171.02 1 6 3.27 −4.02 −0.33 95.55
8b 356.42 1169.84 1 6 3.22 −4.13 −0.38 96.36
8c 356.42 1170.15 1 6 3.22 −4.14 −0.38 94.64
8d 344.38 1111.12 1 5 3.37 −4.29 −0.20 97.80
8e 344.38 1111.09 1 5 3.37 −4.29 −0.20 96.45
8f 360.83 1130.02 1 5 3.53 −4.51 −0.16 98.12
8g 360.83 1139.08 1 5 3.62 −4.66 −0.14 97.86
8h 360.83 1139.13 1 5 3.62 −4.66 −0.14 98.64
8i 405.29 1137.62 1 5 3.60 −4.61 −0.14 99.16
8j 405.29 1147.99 1 5 3.70 −4.77 −0.13 98.20
8k 405.29 1148.04 1 5 3.70 −4.77 −0.13 97.56
8l 351.40 1160.41 1 6 2.37 −4.87 −1.14 86.13
8m 368.43 1216.51 1 6 2.60 −4.12 −0.95 90.86
8n 394.39 1193.18 1 5 4.11 −5.36 −0.04 98.54
8o 354.44 1209.19 1 5 3.80 −5.05 −0.22 99.22
Efavirenz 315.67 880.03 1 3 3.52 −4.86 0.10 94
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methoxyphenyl)acetamide (5f)
Yield 84 %; white solid, MF: C20H24N2O4; MW: 356.18;
MP: 153–155 °C; IR (KBr, ν, cm−1): 3317, 2957, 2920, 2821,
1688, 1615, 1517, 1467, 1253, 1134, 1103; 1H NMR
(400 MHz, CDCl3) δ 9.09 (s, 1H), 7.51 (s, 1H), 7.48 (s, 1H),
6.89 (d, J = 2.2 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 6.67
(s, 1H), 6.55 (s, 1H), 3.90 (s, 3H), 3.87 (s, 3H), 3.81 (s, 3H),
3.76 (s, 2H), 3.32 (s, 2H), 2.92 (s, 4H); MS: m/z 357 (M+ 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-(4-
fluorophenyl)acetamide (5g)
Yield 71 %; white solid, MF: C20H24N2O4; MW: 344.15;
MP: 153–155 °C; IR (KBr, ν, cm−1): 3302, 3070, 2991,2816, 1687, 1612, 1508, 1469, 1228, 1136, 1101; 1H NMR
(400 MHz, CDCl3) δ 9.20 (s, 1H), 7.65 – 7.49 (m, 2H),
7.08 – 7.00 (m, 2H), 6.67 (s, 1H), 6.55 (s, 1H), 3.88 (d, J =
11.6 Hz, 6H), 3.76 (s, 2H), 3.33 (s, 2H), 2.92 (s, 4H), 1.60
(s, 2H); MS: m/z 345 (M+ 1).
N-(2-chlorophenyl)-2-(6,7-dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl)acetamide (5h)
Yield 64 %; white solid, MF: C19H21ClN2O3; MW:
360.12; MP: 109–111 °C; IR (KBr, ν, cm−1): 3298, 2993,
2889, 2833, 1701, 1519, 1436, 1230, 1139, 1103; 1H
NMR (400 MHz, CDCl3) δ 9.97 (s, 1H), 8.48 (dd, J = 8.3,
1.5 Hz, 1H), 7.37 (dd, J = 8.0, 1.4 Hz, 1H), 7.32 (dd, J =
7.5, 1.0 Hz, 1H), 7.10 – 7.01 (m, 1H), 6.67 (s, 1H), 6.55
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2H), 2.94 (s, 4H); MS: m/z 361 (M + 1).
N-(3-chlorophenyl)-2-(6,7-dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl)acetamide (5i)
Yield 69 %; white solid, MF: C19H21ClN2O3; MW:
360.12; MP: 176–178 °C; IR (KBr, ν, cm−1): 3228, 3001,
2821, 2752, 1663, 1517, 1423, 1228, 1138, 1005; 1H
NMR (400 MHz, CDCl3) δ 9.27 (s, 1H), 7.69 (t, J =
2.0 Hz, 1H), 7.45 (ddd, J = 8.2, 2.0, 0.9 Hz, 1H), 7.10
(ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 6.67 (s, 1H), 6.55 (s, 1H),
3.89 (d, J = 12.4 Hz, 6H), 3.76 (s, 2H), 3.33 (s, 2H), 2.92
(d, J = 3.5 Hz, 4H); MS: m/z 361 (M + 1).
N-(4-chlorophenyl)-2-(6,7-dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl)acetamide (5j)
Yield 74 %; white solid, MF: C19H21ClN2O3; MW:
360.12; MP: 177–179 °C; IR (KBr, ν, cm−1): 3269, 2941,
2900, 2825, 2785, 1680, 1517, 1492, 1396, 1253, 1220,
1141, 1105; 1H NMR (400 MHz, CDCl3) δ 9.25 (s, 1H),
7.56 – 7.53 (m, 2H), 7.31 (s, 2H), 6.67 (s, 1H), 6.55 (s,
1H), 3.90 (s, 3H), 3.87 (s, 3H), 3.76 (s, 2H), 3.33 (s, 2H),
2.92 (s, 4H); MS: m/z 361 (M + 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-(4-
nitrophenyl)acetamide (5k)
Yield 67 %; light yellow solid, MF: C19H21N3O5; MW:
371.15; MP: 192–194 °C; IR (KBr, ν, cm−1): 3273, 2933,
2829, 1703, 1504, 1336, 1226; 1H NMR (400 MHz,
CDCl3) δ 9.62 (s, 1H), 8.23 (d, J = 9.2 Hz, 2H), 7.77 (d,
J = 9.2 Hz, 2H), 6.68 (s, 1H), 6.55 (s, 1H), 3.89 (d, J =
14.3 Hz, 6H), 3.78 (s, 2H), 3.38 (s, 2H), 2.94 (s, 4H);
MS: m/z 372 (M + 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-(3-
(trifluoromethyl)phenyl) acetamide (5l)
Yield 68 %; white solid, MF: C20H21F3N2O3; MW:
394.15; MP: 176–178 °C; IR (KBr, ν, cm−1): 3302, 3070,
2991, 2816, 1687, 1612, 1508, 1469, 1228, 1136, 1101; 1H
NMR (400 MHz, CDCl3) δ 9.54 (s, 1H), 7.90 (s, 1H),
7.77 (d, J = 7.9 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.36 (d,
J = 7.7 Hz, 1H), 6.68 (s, 1H), 6.58 (s, 1H), 3.90 (s, 3H),
3.86 (d, J = 9.9 Hz, 5H), 3.73 (d, J = 14.1 Hz, 1H), 3.46
(d, J = 6.7 Hz, 1H), 2.91 (d, J = 5.3 Hz, 2H), 2.88 – 2.76
(m, 2H); MS: m/z 395 (M + 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-(2,6-
dimethylphenyl)acetamide (5m)
Yield 77 %; white solid, MF: C21H26N2O3; MW: 354.19;
MP: 155–157 °C; IR (KBr, ν, cm−1): 3315, 2956, 2920,
2821, 1691, 1610, 1517, 1467, 1253, 1132, 1103; 1H
NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 7.10 (d, J =
1.6 Hz, 3H), 6.66 (s, 1H), 6.56 (s, 1H), 3.88 (d, J = 3.5 Hz,6H), 3.83 (s, 2H), 3.40 (s, 2H), 2.99 (d, J = 5.0 Hz, 2H),
2.95 (d, J = 5.2 Hz, 2H), 2.26 (s, 6H); MS: m/z 355 (M+ 1).
2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-(3,4-
dimethylphenyl)acetamide (5n)
Yield 75 %; white solid, MF: C21H26N2O3; MW: 354.19;
MP: 158–160 °C; IR (KBr, ν, cm−1): 3332, 3045, 2997,
2831, 2773, 1693, 1519, 1489, 1225, 1230, 1138, 1101; 1H
NMR (400 MHz, CDCl3) δ 9.11 (s, 1H), 7.35 (s, 2H),
7.09 (d, J = 7.9 Hz, 1H), 6.67 (s, 1H), 6.55 (s, 1H), 3.90
(s, 3H), 3.87 (s, 3H), 3.76 (s, 2H), 3.33 (s, 2H), 2.92 (s, 4H),
2.25 (d, J = 9.1 Hz, 6H); MS: m/z 355 (M+ 1).
N-(5-chloro-2-methylphenyl)-2-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl) acetamide (5o)
Yield 68 %; white solid, MF: C20H23ClN2O3; MW:
374.14; MP: 117–119 °C; IR (KBr, ν, cm−1): 3277,
3016, 2937, 2900, 2829, 1701, 1514, 1445, 1259, 1228,
1190, 1136; 1H NMR (400 MHz, CDCl3) δ 9.44 (s,
1H), 8.02 (dd, J = 6.7, 2.7 Hz, 1H), 7.22 – 7.12 (m, 2H),
6.67 (s, 1H), 6.54 (s, 1H), 3.88 (d, J = 11.5 Hz, 6H), 3.80 (s,




Yield 73 %; white solid, MF: C20H24N2O4; MW: 356.17;
MP: 91–92 °C; IR (KBr, ν, cm−1): 3419, 3062, 2991, 2833,
1656, 1604, 1514, 1415, 1263, 1234, 1118; 1H NMR
(400 MHz, CDCl3) δ 7.32 (dd, J = 9.4, 4.5 Hz, 1H), 7.12
(s, 1H), 6.69 – 6.64 (m, 2H), 6.64 – 6.53 (m, 2H), 4.76
(s, 1H), 4.58 (s, 1H), 4.06 (s, 1H), 3.93 (t, J = 5.9 Hz, 1H),
3.91 – 3.83 (m, 7H), 3.76 (s, 3H), 3.70 (t, J = 5.9 Hz, 1H),
2.92 (t, J = 5.7 Hz, 1H), 2.86 (t, J = 5.7 Hz, 1H); MS: m/z
257 (M + 1).
1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-(3-
methoxyphenylamino) ethanone (8b)
Yield 79 %; white solid, MF: C20H24N2O4; MW:
356.17; MP: 118–119 °C; IR (KBr, ν, cm−1): 3361, 2999,
2953, 2833, 1643, 1606, 1517, 1421, 1224, 1163, 1112;
1H NMR (400 MHz, CDCl3) δ 7.13 (t, J = 8.1 Hz, 1H),
6.74 – 6.60 (m, 2H), 6.32 (dt, J = 5.8, 3.0 Hz, 2H), 6.22
(d, J = 1.7 Hz, 1H), 4.74 (s, 1H), 4.56 (s, 1H), 3.97 (s, 2H),
3.94 – 3.86 (m, 7H), 3.81 (s, 3H), 3.68 (t, J = 5.9 Hz, 1H),




Yield 83 %; white solid, MF: C20H24N2O4; MW:
356.17; MP: 116–117 °C; IR (KBr, ν, cm−1): 3356,
2951, 2833, 1643, 1517, 1365, 1253, 1211, 1114, 821;
1H NMR (400 MHz, CDCl3) δ 6.83 (d, J = 8.5 Hz,
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3.96 (s, 2H), 3.93 – 3.86 (m, 7H), 3.78 (s, 3H), 3.69
(t, J = 5.9 Hz, 1H), 2.89 (t, J = 5.6 Hz, 1H), 2.83 (t, J =
5.7 Hz, 1H); MS: m/z 257 (M + 1).1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-(3-
fluorophenylamino) ethanone (8d)
Yield 76 %; white solid, MF: C19H21FN2O3; MW:
344.15; MP: 144–145 °C; IR (KBr, ν, cm−1): 3361,
2981, 2910, 2833, 1656, 1612, 1517 1433, 1365, 1253,
1222, 1112; 1H NMR (400 MHz, CDCl3) δ 7.19 –
7.08 (m, 1H), 6.69 – 6.65 (m, 2H), 6.49 – 6.38 (m,
2H), 6.34 (dq, J = 11.5, 2.3 Hz, 1H), 4.75 (s, 1H), 4.57
(s, 1H), 3.96 (d, J = 2.4 Hz, 2H), 3.93 – 3.88 (m, 7H),
3.69 (t, J = 5.9 Hz, 1H), 2.87 (dt, J = 25.9, 5.8 Hz, 2H);
MS: m/z 345 (M + 1).1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-(4-
fluorophenylamino) ethanone (8e)
Yield 81 %; white solid, MF: C19H21FN2O3; MW: 344.15;
MP: 126–12 °C; IR (KBr, ν, cm−1): 3365, 2939, 1837,
1643, 1514, 1440, 1265, 1222, 1116; 1H NMR (400 MHz,
CDCl3) δ 6.93 (t, J = 8.7 Hz, 2H), 6.69 – 6.64 (m, 2H), 6.61
(ddd, J = 8.9, 4.3, 2.1 Hz, 2H), 4.85 (s, 1H), 4.74 (s, 1H),
4.57 (s, 1H), 3.95 (s, 2H), 3.91 – 3.85 (m, 7H), 3.69 (t, J =
5.9 Hz, 1H), 2.90 (t, J = 5.8 Hz, 1H), 2.83 (t, J = 5.9 Hz,
1H); MS: m/z 345 (M+ 1).2-(2-chlorophenylamino)-1-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl) ethanone (8f)
Yield 68 %; white solid, MF: C19H21ClN2O3; MW: 360;
MP: 104–105 °C; IR (KBr, ν, cm−1): 3379, 2999, 2933,
2835, 1665, 1517, 1485, 1415, 1257, 1228, 1209, 1111; 1H
NMR (400 MHz, CDCl3) δ 7.31 (dd, J = 7.9, 1.4 Hz, 1H),
7.17 (t, J = 7.7 Hz, 1H), 6.68 (s, 2H), 6.66 – 6.58 (m, 2H),
4.76 (s, 1H), 4.59 (s, 1H), 4.03 (d, J = 1.9 Hz, 2H), 3.93
(s, 1H), 3.89 (d, J = 3.2 Hz, 6H), 3.70 (t, J = 5.9 Hz, 1H),
2.91 (t, J = 5.7 Hz, 1H), 2.85 (t, J = 5.9 Hz, 1H); MS: m/z
361 (M + 1).2-(3-chlorophenylamino)-1-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)ethanone (8g)
Yield 84 %; white solid, MF: C19H21ClN2O3; MW: 360;
MP: 136–137 °C; IR (KBr, ν, cm−1): 3367, 3053, 2954,
2933, 2833, 1656, 1593, 1514, 1392, 1261, 1228, 1116; 1H
NMR (400 MHz, CDCl3) δ 7.14 – 7.06 (m, 1H), 6.71
(dd, J = 7.9, 1.2 Hz, 1H), 6.67 (d, J = 3.2 Hz, 2H), 6.63 –
6.60 (m, 1H), 6.56 (dt, J = 8.2, 2.2 Hz, 1H), 4.73 (d, J =
15.0 Hz, 1H), 4.57 (s, 1H), 3.97 – 3.92 (m, 2H), 3.89 (dd,
J = 8.1, 5.4 Hz, 7H), 3.68 (t, J = 5.9 Hz, 1H), 2.90 (t, J =
5.9 Hz, 1H), 2.84 (t, J = 5.8 Hz, 1H); MS: m/z 361 (M+ 1).2-(4-chlorophenylamino)-1-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl) ethanone (8h)
Yield 75 %; white solid, MF: C19H21ClN2O3; MW: 360;
MP: 115–116 °C; IR (KBr, ν, cm−1): 3360, 2927, 2906,
2833, 1658, 1600, 1511, 1433, 1265, 1226, 1124; 1H
NMR (400 MHz, CDCl3) δ 7.16 (d, J = 8.7 Hz, 2H),
6.69 – 6.63 (m, 2H), 6.59 (dd, J = 8.9, 2.3 Hz, 2H), 4.74
(s, 1H), 4.57 (s, 1H), 3.95 (d, J = 2.9 Hz, 2H), 3.92 –
3.87 (m, 7H), 3.68 (s, 1H), 2.90 (t, J = 5.9 Hz, 1H), 2.84
(s, 1H); MS: m/z 361 (M + 1).
2-(2-bromophenylamino)-1-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl) ethanone (8i)
Yield 68 %; white solid, MF: C19H21BrN2O3; MW:
404.07; MP: 109–110 °C; IR (KBr, ν, cm−1): 3379, 2999,
2931, 2837, 1649, 1517, 1433, 1442, 1257, 1228, 1207; 1H
NMR (400 MHz, CDCl3) δ 7.50 (dd, J = 9.4, 4.5 Hz, 1H),
7.22 (s, 1H), 6.69 – 6.64 (m, 2H), 6.64 – 6.53 (m, 2H),
4.76 (s, 1H), 4.58 (s, 1H), 4.06 (s, 1H), 3.93 (t, J = 5.9 Hz,
1H), 3.91 – 3.83 (m, 7H), 3.70 (t, J = 5.9 Hz, 1H), 2.91




Yield 75 %; white solid, MF: C19H21BrN2O3; MW:
404.07; MP: 123–124 °C; IR (KBr, ν, cm−1): 3369, 2954,
2931, 2833, 1649, 1591, 1514, 1485, 1433, 1259, 1228,
1112; 1H NMR (400 MHz, CDCl3) δ 7.06 (t, J = 8.0 Hz,
1H), 6.86 (dd, J = 7.8, 1.0 Hz, 1H), 6.77 (dd, J = 4.0,
2.0 Hz, 1H), 6.67 (d, J = 2.7 Hz, 2H), 6.61 (dd, J = 8.2,
2.3 Hz, 1H), 4.75 (s, 1H), 4.57 (s, 1H), 3.95 (d, J = 1.2 Hz,
2H), 3.92 (s, 2H), 3.91 – 3.88 (m, 5H), 3.69 (t, J = 5.9 Hz,
1H), 2.91 (t, J = 5.8 Hz, 1H), 2.84 (t, J = 5.9 Hz, 1H); MS:
m/z 405 (M + 1).
2-(4-bromophenylamino)-1-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)ethanone (8k)
Yield 72 %; white solid, MF: C19H21BrN2O3; MW:
404.07; MP: 117–118 °C; IR (KBr, ν, cm−1): 3358, 2985,
2902, 2833, 1643, 1517, 1433, 1396, 1285, 1224, 1124; 1H
NMR (400 MHz, CDCl3) δ 7.31 (s, 1H), 6.67 (d, J =
5.2 Hz, 2H), 6.64 – 6.45 (m, 3H), 5.02 (s, 1H), 4.74 (s,
1H), 4.57 (s, 1H), 3.94 (s, 2H), 3.91 – 3.87 (m, 7H), 3.68
(t, J = 5.8 Hz, 1H), 2.90 (t, J = 5.8 Hz, 1H), 2.84 (t, J =
6.0 Hz, 1H); MS: m/z 405 (M + 1).
4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-
oxoethylamino)benzonitrile (8l)
Yield 68 %; white solid, MF: C20H21N3O3; MW: 351.16;
MP: 146–147 °C; IR (KBr, ν, cm−1): 3358, 2985, 2902,
2833, 2208, 1643, 1517, 1433, 1396, 1285, 1224, 1124; 1H
NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.5 Hz, 2H), 6.68
(d, J = 4.6 Hz, 2H), 6.65 – 6.62 (m, 2H), 5.60 (s, 1H), 4.75
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3.89 (t, J = 2.7 Hz, 6H), 3.68 (s, 1H), 2.91 (t, J = 5.7 Hz,
1H), 2.85 (t, J = 5.7 Hz, 1H); MS: m/z 352 (M+ 1).
2-(3-acetylphenylamino)-1-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)ethanone (8m)
Yield 66 %; white solid, MF: C21H24N2O4; MW: 368.17;
MP: 111–112 °C; IR (KBr, ν, cm−1): 3365, 2937, 2835,
1672, 1643, 1598, 1517, 1359, 1315, 1259, 1224, 1116; 1H
NMR (400 MHz, CDCl3) δ 7.36 – 7.30 (m, 2H), 7.22 – 7.20
(m, 1H), 6.94 – 6.90 (m, 1H), 6.68 (s, 2H), 4.75 (s, 1H), 4.60
(s, 1H), 4.03 (s, 2H), 3.94 (s, 1H), 3.90 – 3.88 (m, 6H), 3.71
(t, J = 5.9 Hz, 1H), 2.91 (t, J = 5.8 Hz, 1H), 2.84 (t, J =
5.9 Hz, 1H), 2.61 (s, 3H); MS: m/z 369 (M+ 1).
(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-
(3(trifluoromethyl)phenylamino) ethanone (8n)
Yield 76 %; white solid, MF: C20H21F3N2O3; MW:
394.15; MP: 135–136 °C; IR (KBr, ν, cm−1): 3350, 2910,
2835, 1643, 1612, 1514, 1431, 1359, 1284, 1261, 1222,
1109; 1H NMR (400 MHz, CDCl3) δ 7.30 (s, 1H), 6.99
(d, J = 7.7 Hz, 1H), 6.84 (s, 2H), 6.68 (t, J = 3.1 Hz, 2H),
4.76 (s, 1H), 4.59 (s, 1H), 4.00 (s, 2H), 3.92 (s, 1H), 3.90
(d, J = 2.5 Hz, 6H), 3.71 (t, J = 5.9 Hz, 1H), 2.92 (t, J =
5.9 Hz, 1H), 2.85 (t, J = 5.8 Hz, 1H); MS: m/z 395 (M+ 1).
1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-(2,5-
dimethylphenylamino) ethanone (8o)
Yield 75 %; white solid, MF: C21H26N2O3; MW: 354.19;
MP: 140–141 °C; IR (KBr, ν, cm−1): 3402, 2995, 2833,
1643, 1517, 1415, 1255, 1232, 1207, 1112; 1H NMR
(400 MHz, CDCl3) δ 6.67 (d, J = 4.6 Hz, 2H), 6.44 (s,
1H), 6.35 (s, 2H), 4.74 (s, 1H), 4.58 (s, 1H), 3.98 (s, 2H),
3.91 (s, 1H), 3.89 (t, J = 4.3 Hz, 6H), 3.70 (t, J = 5.9 Hz,
1H), 2.90 (t, J = 5.9 Hz, 1H), 2.83 (t, J = 6.0 Hz, 1H), 2.28
(s, 6H); MS: m/z 355 (M + 1).
Conclusion




RT inhibitors. In-vitro screening of the synthesized com-
pounds against HIV-1 RT exhibited weak to significant in-
hibitory activity. Compounds of series 8 exhibited more
significant HIV-1 RT inhibition as compared to the com-
pounds of 5 series. Among the tested compounds, eight-
een compounds (5d, 5f, 5h, 5n, 5o, 8b, 8c, 8e, 8f, 8g, 8h,
8i, 8j, 8k, 8l, 8m, 8n and 8o) exhibited more than 50 %
inhibition at tested 100 μM concentration and two com-
pounds 8h and 8l showed promising inhibition (74.82 and
72.58 %) respectively. SAR analysis of compounds 5a-o
demonstrated that, substitution of phenyl ring with elec-
tron donating group at para position and electronwithdrawing especially chloro at ortho position resulted in
enhanced potency. Among the compounds 8a-o, substitu-
tion with electron withdrawing group of moderate to large
size at para position of phenyl ring significantly increased
the potency against HIV-1 RT. Docked poses of com-
pounds 8h and 8l in the NNIBP of RT showed strong
hydrophobic and hydrophilic interaction, may be respon-
sible for their significant in-vitro activity. Predicted physio-
chemical parameters of the synthesized compounds were
within the acceptable range of drugable properties. Thus
overall SAR studies can help in identification of further
lead as well as in the designing of newer potential inhibi-
tor of HIV-1 RT.
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